文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

抗葡萄球菌β-内酰胺联合标准治疗对MRSA菌血症的疗效:随机临床试验

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该多中心开放标签随机试验纳入352例MRSA菌血症住院成人,比较标准治疗(万古霉素或达托霉素)联合抗葡萄球菌β-内酰胺与标准治疗单用。结果显示联合治疗未显著改善90天复合终点(死亡率、持续性菌血症、复发或治疗失败),且联合组急性肾损伤发生率更高,试验因安全考虑提前终止。

要点

  • 联合β-内酰胺未显著改善90天复合终点(35% vs 39%,绝对差-4.2%)。
  • 联合组第5天持续性菌血症较低(11% vs 20%),但急性肾损伤更高(23% vs 6%)。
  • 因安全担忧提前终止,解读结果需考虑研究可能把握度不足。

核心结论

  • 在MRSA菌血症患者中,标准治疗联合抗葡萄球菌β-内酰胺未显著改善死亡率、持续性菌血症、复发或治疗失败的复合终点。

研究设计与样本

  • 开放标签随机临床试验,2015年8月至2018年7月在4国27家医院纳入352例MRSA菌血症住院成人。
  • 联合组174例接受标准治疗(静脉万古霉素或达托霉素)加抗葡萄球菌β-内酰胺(静脉氟氯西林、氯唑西林或头孢唑林),单用组178例仅接受标准治疗。
  • β-内酰胺疗程为7天,总疗程由治疗医生决定;主要终点为90天复合终点(死亡、第5天持续性菌血症、微生物学复发和治疗失败)。

主要发现

  • 主要终点联合组59例(35%)达到,单用组68例(39%)达到,绝对差-4.2%(95%CI -14.3%至6.0%)。
  • 90天全因死亡联合组35例(21%) vs 单用组28例(16%),差异4.5%(95%CI -3.7%至12.7%)。
  • 第5天持续性菌血症联合组19/166例(11%) vs 单用组35/172例(20%),差异-8.9%(95%CI -16.6%至-1.2%)。
  • 排除基线透析患者后,急性肾损伤联合组34/145例(23%) vs 单用组9/145例(6%),差异17.2%(95%CI 9.3%-25.2%)。

关键数值与推荐

  • 主要终点:90天复合终点(死亡率、第5天持续性菌血症、微生物学复发、微生物学治疗失败)。
  • 联合组第5天持续性菌血症11%(19/166)低于单用组20%(35/172),差异-8.9%(95%CI -16.6%至-1.2%)。
  • 联合组急性肾损伤23%(34/145)高于单用组6%(9/145),差异17.2%(95%CI 9.3%-25.2%)。

临床怎么用

  • 对于MRSA菌血症,不推荐常规加用抗葡萄球菌β-内酰胺以改善复合临床结局。
  • 联合β-内酰胺可能降低第5天持续性菌血症,但需权衡急性肾损伤风险增加。

局限性

  • 试验因安全委员会建议提前终止,实际样本量352例低于计划的440例,可能把握度不足。
  • 开放标签设计可能引入偏倚。
  • β-内酰胺仅使用7天,总疗程由医生决定,可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with mortality of more than 20%. Combining standard therapy with a β-lactam antibiotic has been associated with reduced mortality, although adequately powered randomized clinical trials of this intervention have not been conducted. OBJECTIVE: To determine whether combining an antistaphylococcal β-lactam with standard therapy is more effective than standard therapy alone in patients with MRSA bacteremia. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized clinical trial conducted at 27 hospital sites in 4 countries from August 2015 to July 2018 among 352 hospitalized adults with MRSA bacteremia. Follow-up was complete on October 23, 2018. INTERVENTIONS: Participants were randomized to standard therapy (intravenous vancomycin or daptomycin) plus an antistaphylococcal β-lactam (intravenous flucloxacillin, cloxacillin, or cefazolin) (n = 174) or standard therapy alone (n = 178). Total duration of therapy was determined by treating clinicians and the β-lactam was administered for 7 days. MAIN OUTCOMES AND MEASURES: The primary end point was a 90-day composite of mortality, persistent bacteremia at day 5, microbiological relapse, and microbiological treatment failure. Secondary outcomes included mortality at days 14, 42, and 90; persistent bacteremia at days 2 and 5; acute kidney injury (AKI); microbiological relapse; microbiological treatment failure; and duration of intravenous antibiotics. RESULTS: The data and safety monitoring board recommended early termination of the study prior to enrollment of 440 patients because of safety. Among 352 patients randomized (mean age, 62.2 [SD, 17.7] years; 121 women [34.4%]), 345 (98%) completed the trial. The primary end point was met by 59 (35%) with combination therapy and 68 (39%) with standard therapy (absolute difference, -4.2%; 95% CI, -14.3% to 6.0%). Seven of 9 prespecified secondary end points showed no significant difference. For the combination therapy vs standard therapy groups, all-cause 90-day mortality occurred in 35 (21%) vs 28 (16%) (difference, 4.5%; 95% CI, -3.7% to 12.7%); persistent bacteremia at day 5 was observed in 19 of 166 (11%) vs 35 of 172 (20%) (difference, -8.9%; 95% CI, -16.6% to -1.2%); and, excluding patients receiving dialysis at baseline, AKI occurred in 34 of 145 (23%) vs 9 of 145 (6%) (difference, 17.2%; 95% CI, 9.3%-25.2%). CONCLUSIONS AND RELEVANCE: Among patients with MRSA bacteremia, addition of an antistaphylococcal β-lactam to standard antibiotic therapy with vancomycin or daptomycin did not result in significant improvement in the primary composite end point of mortality, persistent bacteremia, relapse, or treatment failure. Early trial termination for safety concerns and the possibility that the study was underpowered to detect clinically important differences in favor of the intervention should be considered when interpreting the findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02365493.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Tong SYC, Lye DC, Yahav D, et al. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA. 2020. PMID: 32044943. doi:10.1001/jama.2020.0103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。